Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.16.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.34.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JD.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.79NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HP.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.35NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.44NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EF.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.84NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EU.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.97NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FE.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.3.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.95NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
ET.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.47NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.58NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.2.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.96NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EZ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.8.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GD.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBZNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BR.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used